ArticleBioinformatics (Oxford, England)2026
RGCNMDA: pathway-bridged relational graph learning with adaptive multi-view fusion for human miRNA-disease association prediction.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- RGCNMDA: pathway-bridged relational graph learning with adaptive multi-view fusion for human miRNA-disease association prediction.Bioinformatics (Oxford, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
motivationMicroRNAs are key post-transcriptional regulators whose dysregulation is associated with complex human diseases. Computational prediction can prioritize candidate miRNA-disease associations, but reliable evaluation is complicated by sparse labels, cold-start entities, limited biological context in bipartite graphs, and leakage when association-derived features are constructed before data splitting.
resultsWe present RGCNMDA, a leakage-controlled multi-view framework that integrates global latent structure, local profiles and similarities, and pathway context. Within every fold, interaction profiles, GIP similarities, PCA inputs, MDMF factors, and miRNA-disease graph edges are reconstructed exclusively from training positives. Four independent factorized encoders transform the miRNA and disease interaction profiles and GIP similarities, while a fold-local MDMF branch captures global latent structure. These representations are integrated with a pathway-bridged graph containing miRNA, disease, and pathway nodes connected by six directed relation types. A relational graph convolutional network performs type- and direction-specific message passing, and node-wise gates adaptively fuse graph, MDMF, and combined profile and similarity representations before an MLP pair decoder scores candidate associations. On HMDD v4.0, RGCNMDA achieved AUCs of 0.9589, 0.9109, and 0.8836 under random, cold-disease, and cold-miRNA evaluation, respectively; on the processed independent-source RNADisease v4.0 benchmark, the corresponding values were 0.9580, 0.8446, and 0.8913. Same-protocol baseline comparisons and diagnostic analyses showed that the benefits of RGCNMDA were setting dependent, with the strongest pathway-related improvement under cold-disease evaluation. These results support the robustness of leakage-controlled multi-view learning across standard and cold-start evaluation settings. AVAILABILITY AND IMPLEMENTATION: https://github.com/hnuchao/pathway-RGCNMDA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.